Combined Tirzepatide and Menopause Hormone Therapy Leads to Increased Weight Loss in Postmenopausal Women

Postmenopausal women with overweight or obesity achieved greater weight loss when using tirzepatide in combination with menopause hormone therapy compared to those using tirzepatide alone. A recent study presented at the Endocrine Society's annual meeting found that the combined treatment resulted in a 17% total body weight loss percentage, surpassing the 14% achieved with tirzepatide alone. Moreover, 45% of women using tirzepatide plus menopause hormone therapy achieved at least 20% total body weight loss, a significantly higher percentage than the 18% of those using tirzepatide alone.

Key Takeaways:

• The study involved 120 postmenopausal women with overweight or obesity, with a median duration of 18 months.
• The combined use of tirzepatide and menopause hormone therapy led to a 17% total body weight loss percentage, compared to 14% with tirzepatide alone.
• 45% of women using tirzepatide plus menopause hormone therapy achieved at least 20% total body weight loss, compared to 18% of those using tirzepatide alone.
• The study's results suggest that combining tirzepatide with menopause hormone therapy may be an effective strategy for weight loss in postmenopausal women.
• Regina Castaneda, M.D., research fellow for the Division of Endocrinology at the Mayo Clinic, highlighted the potential broader efficacy trend for pairing obesity medications with menopause hormone therapy.
• The study underscores the urgent need for further research to better understand how obesity medications and menopause hormone therapy work together.

Statistics:

• 17% total body weight loss percentage achieved with combined tirzepatide and menopause hormone therapy.
• 14% total body weight loss percentage achieved with tirzepatide alone.
• 45% of women using tirzepatide plus menopause hormone therapy achieved at least 20% total body weight loss.
• 18% of women using tirzepatide alone achieved at least 20% total body weight loss.
• 120 postmenopausal women participated in the study, with a median duration of 18 months.

Sources:

• Endocrine Society
• Regan Castaneda, M.D. (research fellow for the Division of Endocrinology at the Mayo Clinic)
• Maria Daniela Hurtado Andrade, M.D., Ph.D. (assistant professor of medicine and consultant for the Division of Endocrinology at the Mayo Clinic)
• National Institutes of Health Bridging Interdisciplinary Careers in Women's Health Research Grant
• Mayo Clinic Center for Women's Health Research